Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DROP-FPF: Nerandomilast to reduce worsening of interstitial lung abnormalities in individuals with familial risk of pulmonary fibrosis
jRCT2031250414Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Feb 2026
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in pulmonary fibrosis (PF) and interstitial lung disease (ILD) comparing Nerandomilast with Placebo (2 arms). Primary endpoint: Time to physiologic or radiologic worsening of ILA/ILD over the whole trial. Started Feb 2026; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
pulmonary fibrosis (PF)interstitial lung disease (ILD)
Beyond the preview
Go deeper on jRCT2031250414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250414.